Visit | Mean | SD | Change from screen (%) | p Value | |
Eotaxin-1+ cells per hpf | |||||
Mepolizumab (n = 5) | Screening | 84.12 | 31.76 | ||
Week 4 | 24.95 | 10.15 | −70 | 0.0001 | |
Week 13 | 20.89 | 13.91 | −75 | 0.0002 | |
Placebo (n = 6) | Screening | 49.47 | 21.47 | ||
Week 4 | 42.83 | 27.27 | −13 | NS | |
Week 13 | 41.53 | 26.78 | −16 | NS | |
Eotaxin-2+ cells per hpf | |||||
Mepolizumab (n = 5) | Screening | 90.84 | 38.41 | ||
Week 4 | 19.27 | 10.66 | −79 | 0.0001 | |
Week 13 | 23.45 | 20.65 | −74 | 0.0005 | |
Placebo (n = 6) | Screening | 58.99 | 29.41 | ||
Week 4 | 47.13 | 28.15 | −20 | NS | |
Week 13 | 52.14 | 30.08 | −12 | NS | |
Eotaxin-3+ eosinophils per hpf | |||||
Mepolizumab (n = 5) | Screening | 62.63 | 38.48 | ||
Week 4 | 14.63 | 6.31 | −77 | 0.0007 | |
Week 13 | 19.72 | 22.23 | −69 | 0.0041 | |
Placebo (n = 6) | Screening | 45.01 | 35.39 | ||
Week 4 | 36.14 | 21.94 | −19 | NS | |
Week 13 | 39.19 | 32.63 | −13 | NS | |
Eotaxin-3 expression by epithelial cells (score) | |||||
Mepolizumab (n = 5) | Screening | 1.2 | 1.4 | ||
Week 4 | 1.5 | 1.7 | +25 | NS | |
Week 13 | 1.2 | 1.4 | 0 | NS | |
Placebo (n = 6) | Screening | 1.5 | 1.4 | ||
Week 4 | 2.0 | 1.5 | +33 | NS | |
Week 13 | 1.75 | 1.5 | +17 | NS | |
IL-5+ cells per hpf | |||||
Mepolizumab (n = 5) | Screening | 72.17 | 43.79 | ||
Week 4 | 28.87 | 18.53 | −60 | 0.006 | |
Week 13 | 29.91 | 27.31 | −59 | 0.004 | |
Placebo (n = 6) | Screening | 53.93 | 33.81 | ||
Week 4 | 49.53 | 19.72 | −8 | NS | |
Week 13 | 48.61 | 27.29 | −10 | NS | |
TNFα expression by epithelial cells (score) | |||||
Mepolizumab (n = 5) | Screening | 2.4 | 0.5 | ||
Week 4 | 2.3 | 0.5 | −4 | NS | |
Week 13 | 2.3 | 0.5 | −4 | NS | |
Placebo (n = 6) | Screening | 2.5 | 0.6 | ||
Week 4 | 2.25 | 0.6 | −10 | NS | |
Week 13 | 2.1 | 0.7 | −16 | NS | |
EDN expression by eosinophils (score) | |||||
Mepolizumab (n = 5) | Screening | 1.80 | 0.45 | ||
Week 4 | 1.25 | 0.44 | −31 | 0.0001 | |
Week 13 | 1.26 | 0.45 | −30 | 0.0001 | |
Placebo (n = 6) | Screening | 1.66 | 0.38 | ||
Week 4 | 1.24 | 0.62 | −25 | 0.006 | |
Week 13 | 1.64 | 0.66 | −1 | NS | |
Extracellular EDN deposition (score) | |||||
Mepolizumab (n = 5) | Screening | 2.11 | 0.44 | ||
Week 4 | 1.74 | 0.68 | −18 | 0.0073 | |
Week 13 | 1.65 | 0.17 | −22 | 0.0007 | |
Placebo (n = 6) | Screening | 2.06 | 0.48 | ||
Week 4 | 1.81 | 0.61 | −12 | NS | |
Week 13 | 2.01 | 0.46 | −2 | NS |
EDN, eosinophil-derived neurotoxin; hpf, high power field; IL-5, interleukin-5; NS, non-significant; TNFα, tumour necrosis factor α.